In recent decades, rapid progression of monoclonal antibody (mAb) development has culminated in approvals for more than one hundred therapeutics in the United States. mAbs enhance the immune response ...

The emergence of antibody-drug conjugates (ADCs) has seen them become a promising class of anticancer therapeutics, exhibiting better precision and reduced off-target toxicity in targeting cancer ...

ADCs integrate monoclonal antibodies with cytotoxic payloads, offering new treatment options for NSCLC, including biomarker-selected and biomarker-agnostic patients. ADCs are composed of an antibody, ...